Preliminary Recommendation on Tenofovir/Lamivudine/Dolutegravir (TLD)
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 23 August 2021.) Document Preview:
Evidence brief for 31 July to 06 August 2021
For the period of 31 July to 06 August 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 31 July to 06 August 2021
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19 (June Reassessment)
Date of publication: June 25, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19 (June Reassessment)
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19 (June Reassessment)
Date of publication: June 25, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in continue reading : BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19 (June Reassessment)